LIfT’s CEO challenges out dated thinking that therapies focused on T-Cells alone are enough to achieve complete remission in most solid tumours

During a presentation at the Biotech Showcase, our CEO, Alex Blyth challenged the current view that T-cells can do it all, highlighting the roles neutrophils play in tumour micro-environments (TME) in orchestrating the working together of the immune cells. The future of curing cancer relies on cells working together, and LIfT’s Immuno-Modulatory Alpha Neutrophils (IMANs) rebalance the TME against the tumour and opens the tumour and recruit in the rest of the immune cells. LIfT’s immuno-modulatory alpha neutrophils (IMANs) can be enhanced further by combinations with monoclonal antibodies (MAbs) acting on the antibody-dependent cellular cytotoxicity (ADCC) pathway, checkpoint inhibitors (CPIs) and other cell and immuno-oncology (IO) therapies.